(VIANEWS) – EQUASENS (EQS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EQUASENS (EQS.PA) | €50.80 | 2.44% | 27.25% |
| MEDISTIM (MEDI.OL) | kr187.50 | 2.21% | 32.37% |
| EUROFINS SCIENT. (ERF.PA) | €56.24 | 1.8% | 6.16% |
| UCB (UCB.BR) | €109.25 | 1.25% | 3.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EQUASENS (EQS.PA)
2.44% Forward Dividend Yield and 27.25% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.19.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 15.92. Meaning, the purchaser of the share is investing €15.92 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.
Moving Average
EQUASENS’s worth is under its 50-day moving average of €53.93 and way below its 200-day moving average of €67.84.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EQUASENS’s stock is considered to be oversold (<=20).
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was 2.09%, 0.32%, and 1.67%.
EQUASENS’s highest amplitude of average volatility was 2.09% (last week), 1.51% (last month), and 1.67% (last quarter).
More news about EQUASENS.
2. MEDISTIM (MEDI.OL)
2.21% Forward Dividend Yield and 32.37% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.41.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 29.25. Meaning, the purchaser of the share is investing kr29.25 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.21%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 97.92.
More news about MEDISTIM.
3. EUROFINS SCIENT. (ERF.PA)
1.8% Forward Dividend Yield and 6.16% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 35.82. Meaning, the purchaser of the share is investing €35.82 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Moving Average
EUROFINS SCIENT.’s value is below its 50-day moving average of €56.52 and above its 200-day moving average of €55.77.
More news about EUROFINS SCIENT..
4. UCB (UCB.BR)
1.25% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.76.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 62.07. Meaning, the purchaser of the share is investing €62.07 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Yearly Top and Bottom Value
UCB’s stock is valued at €109.25 at 01:30 EST, below its 52-week high of €109.40 and way above its 52-week low of €65.40.
Volume
Today’s last reported volume for UCB is 112459 which is 63.99% below its average volume of 312300.
Moving Average
UCB’s value is way higher than its 50-day moving average of €87.80 and way above its 200-day moving average of €80.50.
Sales Growth
UCB’s sales growth for the current quarter is 6.5%.
More news about UCB.
